Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Applied Biologics extends longstanding system-wide agreement with Providence Health & Services for XWRAP®.
-
Applied Biologics initiates multi-center real-world outcomes study of XWRAP® across chronic wound types.
-
Applied Biologics announces submission of XWRAP® translational research abstract to SAWC Fall 2026.
-
Applied Biologics introduces ECM Preservation Technology™ (EPT™), the proprietary manufacturing platform behind XWRAP®.
-
Applied Biologics' VA FSS contract shifts to Evergreen structure, enabling potential XWRAP® access for up to 20 years.
-
Applied Biologics expands strategic focus to surgical applications of XWRAP® across multiple specialties.
-
Applied Biologics expands its national commercial organization to support XWRAP® growth and future pipeline commercialization.
-
Applied Biologics completes translational study showing XWRAP® exhibits favorable wound-healing biology vs. conventional placental tissue processing.
-
Applied Biologics submits CAMPX Trial abstract to SAWC Fall 2026, showing XWRAP improved DFU closure rates to 30.9% vs. 17.5% for standard of care alone.
-
XWRAP showed statistically significant wound closure improvement vs. standard of care alone in the CAMPX RCT — 31% vs. 18% (ITT, p=0.023).